
GE Healthcare Announces FDA Approval for Allia IGS Pulse for Cardiac Imaging Procedures
GE HealthCare has announced the FDA clearance of Allia IGS Pulse to the existing portfolio of GE HealthCare’s image-guided systems (IGS). The system is engineered to provide high quality imaging for cardiology interventions while maintaining the right dose for optimal visibility, even for complex cases.
A survey of interventionalists revealed that almost 50% of interventional procedures are carried out in situations where clinicians have limited access to user interface functions and display. To address these challenges, Allia IGS Pulse offers a customized workspace tailored to the specific needs and preferences of operators. The system introduces the first monopolar x-ray tube for capturing images during interventional procedures. Additionally, the compact design of the new tube enables clinicians to achieve steep angulations, providing better insights into coronary artery anatomy, even with 30cm detector configurations. Furthermore, the system incorporates the latest version of MyIQ technology, allowing clinicians to choose from four different image styles with a single click for a personalized experience at no additional dose.
The imaging system can also be used for large and bariatric patients with a BMI exceeding 30 and the platforms technology minimize motion blur, resulting in improved visualization of dynamic elements such as vessels and devices. The introduction of AutoRight PLUS, an advanced automation platform leveraging AI, optimizes seven parameters in real time, including Focal Spot Shape, thus relieving clinicians from manual adjustments during procedures. This innovation allows healthcare providers to remain fully focused on patient care. The technology also allows the operator a suite of tools to support dose efficiency or the patient, reduction, and awareness. Allia IGS Pulse has already been in pilot operations at Clinique Pasteur – Toulouse in France since January 2023.
Dr. Nicolas Dumonteil, an Interventional Cardiologist at Clinique Pasteur, Toulouse, attests to the significant benefits of the Allia IGS Pulse system. He notes improvements in imaging quality, reduced noise, adaptability, and versatility across various daily situations and procedures. Dr. Raphaël Philippart, another Interventional Cardiologist at Clinique Pasteur, emphasizes the enhanced image quality, particularly for obese patients and complex angioplasties where visibility of guidewires, balloons, and stents is crucial.
The company is formally launching the Allia IGS Pulse at the upcoming Transcatheter Cardiovascular Therapeutics 2023 conference (TCT).